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Abstract
Mucopolysaccharidoses (MPS) are rare lysosomal disorders caused by the deficiency of specific lysosomal en-
zymes responsible for glycosaminoglycan (GAG) degradation. Enzyme Replacement Therapy (ERT) has been
shown to reduce accumulation and urinary excretion of GAG, and to improve some of the patients' clinical signs. We
studied biochemical and molecular characteristics of nine MPS patients (two MPS I, four MPS II and three MPS VI)
undergoing ERT in northern Brazil. The responsiveness of ERT was evaluated through urinary GAG excretion mea-
surements. Patients were screened for eight common MPS mutations, using PCR, restriction enzyme tests and di-
rect sequencing. Two MPS I patients had the previously reported mutation p.P533R. In the MPS II patients, mutation
analysis identified the mutation p.R468W, and in the MPS VI patients, polymorphisms p.V358M and p.V376M were
also found. After 48 weeks of ERT, biochemical analysis showed a significantly decreased total urinary GAG excre-
tion in patients with MPS I (p < 0.01) and MPS VI (p < 0.01). Our findings demonstrate the effect of ERT on urinary
GAG excretion and suggest the adoption of a screening strategy for genotyping MPS patients living far from the main
reference centers.
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The mucopolysaccharidoses (MPS) are a rare group
of lysosomal storage diseases (LSD) with an autosomal re-
cessive inheritance pattern (with the exception of MPS II,
which is an X-linked) and characterized by the accumula-
tion of glycosaminoglycans (GAG) in the lysosomes. This
accumulation occurs due to low or absent lysosomal en-
zyme activity, essential to the GAG catabolism, and results
in systemic impairment of organs and tissues (Neufeld and
Muenzer, 2001).
With an incidence ranging from 1:10000 to 1:25000
newborns worldwide, MPS appear to be among the most
frequent LSDs. MPS I and II were found to be the most fre-
quent, while MPS VI is reported to have a lower incidence
(Solyom, 1996; Meikle et al., 1999). The MPS Brazil Net-
work, an initiative created to improve the diagnosis and
management of these diseases in Brazil between 2004 and
2006, identified 161 MPS patients, among which MPS II
showed the highest incidence (n = 82) and MPS VII the
lowest (n = 4). Castro et al. (2007) reported a high inci-
dence of MPS II and VI in patients from northern Brazil,
followed by MPS I.
So far, eleven different subtypes of MPS have been
identified (Neufeld and Muenzer, 2001). Patients with
MPS present similar chronic and progressive clinical fea-
tures, but symptoms may vary depending on the type.
Organomegaly,dysostosismultiplex,hepatosplenomegaly,
joint contractures and characteristic facial changes are
common symptoms described in these patients. Other sys-
temic impairments may also occur, such as hearing defi-
ciencies,cardiorespiratorydisorders,lowarticularmobility
and loss of visual acuity (Neufeld and Muenzer, 2001;
Muenzer, 2004).
Enzyme Replacement Therapy (ERT) is considered
an efficient therapeutic method in MPS treatment. It is
based on the periodic replacement of the defective enzyme,
leading to higher GAG degradation in tissues and organs,
Genetics and Molecular Biology, 34, 3, 410-415 (2011)
Copyright © 2011, Sociedade Brasileira de Genética. Printed in Brazil
www.sbg.org.br
Send correspondence to Luiz Carlos Santana da Silva. Laboratório
de Erros Inatos do Metabolismo, Instituto de Ciências Biológicas,
UniversidadeFederaldoPará,R.AugustoCorrêan.01,66075-110
Belém, PA, Brazil. E-mail: lcss@ufpa.br.
Short Communicationpromoting a significant improvement in some clinical fea-
tures. However, the influence of ERT on other pathological
manifestations, like progressive skeletal disease, arthro-
pathy,centralnervoussystemdysfunction,cardiacinvolve-
ment and visual impairment, is still not well understood
(Miebach, 2005; Arora et al., 2007; El Dib and Pastores,
2007; Pitz et al., 2009).
Previous studies have proposed urinary GAG dosage
as a biochemical parameter for evaluating the efficacy of
ERT protocols. After some months of treatment, the major-
ity of patients undergoing ERT showed an improvement of
many clinical symptoms, which was correlated with a sig-
nificant reduction in urinary GAG excretion (Harmatz et
al., 2005, 2008; Arora et al., 2007; Sifuentes et al., 2007;
Muenzer et al., 2009).
The isolation and characterization of genes involved
in the depletion of GAG catabolism enzymes led to the
identification of many disease-causing mutations related to
MPS. Despite the great variability presented by MPS pa-
tients,somemutationswerereportedtobefrequentinsome
specific populations (Matte et al., 2000; Petry et al., 2005;
Alves et al., 2006; Mangas et al., 2008).
The aims of this study were to investigate common
MPS mutations in patients from northern Brazil and to ana-
lyze the efficacy of ERT by means of urinary GAG mea-
surements.
We studied nine patients with MPS from a region in
northern Brazil (state of Pará), two of which with MPS I,
four with MPS II, and three with MPS VI. The diagnoses,
madebytheMedicalGeneticsService(SGM)oftheHospi-
tal de Clínicas de Porto Alegre, were based on abnormal
urinary GAG excretion (before starting ERT) and leuko-
cyte enzyme activity. All patients had clinical manifesta-
tions of the disease, and the diagnosis was confirmed by a
leukocyte enzyme activity < 20% of the normal range es-
tablishedbyourlaboratory.Someclinicalparameters,such
as age, consanguinity, height, corneal opacification and
cardiac dysfunctions, were analyzed in each patient, for
phenotype determination (Table 1). This study was re-
viewed and approved by the Human Research Ethics Com-
mittee of the Instituto de Ciências da Saúde, Universidade
Federal do Pará (protocol no. #172/2008 - November 11
th,
2008).
The recombinant enzymes laronidase (Aldurazy-
me®, recombinant human -L-iduronidase; BioMarin
Pharmaceutical Inc., Novato, CA, USA; Genzyme Corpo-
ration, Cambridge, MA, USA) and galsulfase (Naglazy-
me®, recombinant human ASB; BioMarin Pharmaceutical
Inc., Novato, CA, USA) were administered intravenously
once a week for 48 weeks, at a dosage of 1 mg/kg body-
weightforMPSI,and0.58mg/kgbodyweightforMPSVI,
respectively. For MPS II ERT, idursulfase (Elaprase®,
Shire HGT) at a dosage of 0.50 mg/kg was intravenously
administered.
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.Genomic DNA was extracted from peripheral blood
using the phenol-chloroform technique (Sambrook and
Russel, 2001). PCR reactions and restriction enzyme tests
were designed to screen for eight known MPS mutations:
p.Q70X, p.W402X and p.P533R (IDUA gene, MPS I);
p.R468W, p.R468Q and p.P467L (IDS gene, MPS II);
p.R315Q and 1533del23 (ARSB gene, MPS VI), with the
exception of exons 3 and 9 (IDS gene), which were directly
sequenced after amplification.
PCR was performed in a total reaction volume of
50 L, containing 100 ng of DNA, 2 mmol/L of dNTP, 1x
PCR buffer (10 mmol/L TRIS-HCl, pH 8.3; 50 mmol/L
KCl), 20 pmol of each primer (forward and reverse),
1.5 mmol/L MgCl2, and 1U of Taq DNA polymerase (Invi-
trogen). Cycling conditions were typically 94 °C for 5 min,
followed by 35 cycles of 1 min at 94 °C, 1 min at 55-66 °C,
1minat72°C,andafinalextensionat72°Cfor10min.All
amplificationswerecarriedoutinanMG96+Peltier-Based
Thermal Cycler (Biosystems). For control, PCR reactions
with no DNA (blank) were used during each reaction. The
amplified fragments were visualized in 2% agarose gel
containing ethidium bromide.
Afteramplification,thePCRproductsweresubjected
to direct sequencing for mutation and/or polymorphism de-
tection, using the BigDye 3.1 Terminator Cycle Sequen-
cing kit (Applied Biosystems, Foster City, CA), in an ABI
PRISM 377 DNA Sequencer (Applied Biosystems). Some
sequence changes were confirmed by digestion with spe-
cific restriction enzymes. Targeted mutations, primer se-
quences, fragment lengths and restriction enzymes are
presented in Table 2.
The total GAG concentration in urine samples of
MPS patients undergoing ERT was determined by a
method based on spectrophotometric detection of meta-
chromatic changes to the 1,9-dimethylmethylene blue
(DMB) dye, resulting from GAG binding (Whitley et al.
1989). Urinary creatinine concentrations were also mea-
sured separately in order to normalize urinary GAG con-
centrations (mg GAG/mmol creatinine). Condroitin sulfate
was used as standard control in DMB binding measure-
ments.
For the urinary GAG concentrations, all descriptive
statistics, including means, standard deviations (SD), and
percent change over time were calculated using the Biostat
5.0 Software. Changes in parameters between baseline (be-
fore starting treatment) and after 48 weeks of ERT were
evaluated using Student's t test (p = 0.05).
After amplification and direct sequencing of the am-
plifiedfragments,twopreviouslydescribedmutationswere
identified among the nine studied MPS patients: mutation
p.P533R, common in patients with MPS I, was detected in
patient P1 (homozygous) and patient P2 (heterozygous);
another mutation, frequent in MPS II patients (p.R468W),
was identified only in patient P3. In addition, two common
polymorphisms (p.V358M and p.V376M) were found in
MPS VI patients.
A significant decrease in relative urinary GAG con-
centrationwasobservedinallpatientswithMPSIundergo-
412 Mucopolysaccharidosis northern Brazil
Table 2 - Sequence and orientation of primer pairs used for amplification of MPS gene fragments.
MPS Subtype Mutation Primer (5’  3’) Product size (bp) Restriction enzyme Product size (bp)
MPS I p.Q70X
(exon 2)
GGCTTGAACGTGTGTGTCAG (F)
TCCCATCTGTGCCTCTGTAA (R)
274 -Sau96I N:122+95+57
M:179+95
MPS I p.W402X
(exon 9)
CTGGGGACTCCTTCACCAAG (F)
CAGAGACCTCCCTGGAACC (R)
354 +BfaI N:354
M: 227+ 127
MPSI p.P533R
(exon 11)
GTGTGGGTGGGAGGTGGA (F)
TTAGGGGACTGCCACTTGC (R)
250 - -
MPS II Exon 3 AAGCATCTGCTGGTTTCAGG (F)
CAGACTCTGGACATGGAGCA (R)
423 - -
MPS II p.R468W
(exon 9 I)
CATATGGAGCCCAGACAGGT (F)
ATGCTGCGTATGGAATAGCC (R)
399 -MspI N:316+83
M:399
MPS II p.R468Q
(exon 9 I)
CATATGGAGCCCAGACAGGT (F)
ATGCTGCGTATGGAATAGCC (R)
399 -TaqI N:241+158
M:399
MPS II p.P467L
(exon 9 I)
CATATGGAGCCCAGACAGGT (F)
ATGCTGCGTATGGAATAGCC (R)
399 -NciI N:316+83
M:399
MPS II Exon 9 II CCCGTGAACTGATTGCCTAT (F)
ACTAGCCCTCAGGCTGCTTC (R)
400 - -
MPS VI p.R315Q
(exon 5)
TCATCCTCATGCCAAGACCT (F)
GAAAAAGGGCAGGGTGTAGG (R)
300 -TaqI N:179+77+44
M:256+44
MPS VI 1533del23
(exon 8)
CCTCTGTGCTTCTCCCTCAG (F)
CTTCCAATTGAAAGGTTTTC (R)
347 - -
(F)forward;(R)reverse;N:normal;M:mutant;+/-gainorlossofrestrictionenzymesite,respectively.Allprimersweredesignedbyourgroup,usingthe
Primer3 Software (http://www.genome.wi.mit.edi/cgi-bin/primer3_www.cgi).ing ERT when compared to baseline (Figure 1). In patient
P1, the initial urinary GAG concentration of 76.38 mg
GAG/mmol creatinine (single dosage) decreased to
12.34  9.35 mg GAG/mmol creatinine at week 6, repre-
sentingareductionofapproximately84%(p<0.001)inthe
urinary GAG excretion rate. This reduction became more
evident in the subsequent weeks, reaching values of
10.20  6.89 mg GAG/mmol creatinine (86% reduction)
during week 12, and this level was maintained until the end
of the analyzed period (48 weeks).
Patient P2 (MPS I) also presented a significant reduc-
tion in urinary GAG excretion after starting ERT. At base-
line, the urinary GAG concentration was 17.27 mg
GAG/mmol creatinine, and at week 6 this excretion was re-
duced to 9.17  4.1, which corresponds to a 47% reduction
(p < 0.05). However, at week 12, these values had oscil-
lated, returning to higher levels (16.4  7.6 mg GAG/mmol
creatinine)decreasingagainbyweeks18and24(11.17.2
and 4.3  0.53 mg GAG/mmol creatinine, respectively). In
this patient (P2), the urinary GAG concentrations could not
be measured after week 24, because at that time his treat-
ment was discontinued.
Patient P5 (MPS II) also presented a significant re-
duction in urinary GAG excretion after starting ERT. At
baseline, the urinary concentration was 12.41 mg
GAG/mmol creatinine, decreasing to 4.2 mg GAG/mmol
creatinine by week 5, a reduction of approximately 66%
(data not shown).
Patients with MPS VI also showed a significant re-
duction in their urinary GAG excretion during ERT (Figu-
re 2). In patient P7, the mean value of urinary GAG
excretion at baseline was 31.9 mg GAG/mmol creatinine.
After starting ERT, this concentration had decreased to
6.17  2.79 mg GAG/mmol creatinine by week 6, a reduc-
tion of approximately 81% (p < 0.01). This concentration
remained stable until week 36, when a discrete but not sig-
nificant(p>0.05)increasewasobservedcomparedtobase-
line. Changes in urinary GAG concentration were also ob-
served in patient P8, who presented a significant reduction
of 88% (p < 0.01) at week 6 (3.16  0.80 mg GAG/mmol
creatinine) as compared to baseline (26.92 mg GAG/mmol
creatinine).
In this study, we found two targeted mutations:
p.P533R in two patients with MPS I, and p.R468W in one
patient with MPS II. Moreover, two previously described
polymorphisms (p.V358M and p.V376M) were detected in
patientswithMPSVI.Noneoftheotherinvestigatedmuta-
tions were found.
Mutation p.P533R, identified in homozygosis in pa-
tient P1 and in heterozygosis in patient P2, has been previ-
ously reported in Brazilian patients by Matte et al. (2003),
who described different phenotypes in patients with the
same mutation. Previously, Gatti et al. (1997) and Venturi
et al. (2002) had also reported variable phenotypes in the
presenceofthep.P533RmutationinItalianMPSIpatients.
PatientP3(MPSII),whopresentedthep.R468Wmu-
tation, had a phenotype classified as severe, differing from
results reported in the literature.
This difficulty in establishing genotype/phenotype
correlations may result from some unaccounted factors,
such as the rarity of this disease and the inheritance profile
of the mutations.
Somestudiessuggestthatcertainmutationsinvolving
C>To rG>Atransitions in CpG dinucleotides are due to
in situ methylation-deamination processes and, therefore,
these regions are considered hotspots for mutation identifi-
cation. The p.R468W mutation is caused byaC>Tchange
in CpG regions and is, therefore, considered a hotspot.
However,itsroleinphenotypedeterminationisnotyetwell
understood, due to the high heterogeneity of this gene.
According to Froissart et al. (2007), seven out of
eight patients with attenuated phenotypes carried a mis-
sense mutation, including p.R468W. Jonsson et al. (1995)
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Figure 1 - Urinary GAG excretion in patients with MPS I during ERT.
Values represent the 6-week means of GAG excretion for patient P1 (dark
line)andpatientP2(grayline).Themeanreductionwassignificantinboth
patients when compared to GAG concentration at baseline (p < 0.01).
MeasurementsofGAGexcretionofpatientP2afterweek24werenotpos-
sible because his treatment was discontinued. Error bars represent the
standard deviation of the measurement in each analyzed week.
Figure 2 - Urinary GAG excretion in patients with MPS VI during ERT.
Values represent the 6-week means of GAG excretion for patient P7 (dark
line)andpatientP8(grayline).Themeanreductionwassignificantinboth
patients when compared to GAG concentration at baseline (p < 0.01). Er-
ror bars represent the standard deviation of the measurement in each ana-
lyzed week.hadalsodescribedthreepatientswiththismutation,allpre-
sentingamildphenotype.Incontrast,Froissartetal.(2007)
themselves,besidesotherauthors(Isogaietal.,1998;Linet
al., 2006), reported severe phenotypes associated to this
mutation in different patients. On the other hand, Li et al.
(1999) did not report the phenotypic classification of their
patients, due to lack of clinical data.
The polymorphisms p.V358M and p.V376M were
detected in patients P8 and P9, respectively, both present-
ingaseverephenotype.Thesepolymorphismsarealsopro-
duced by transitions at CpG nucleotides and, when
associated with some disease-causing mutations, can con-
tribute for a decrease in enzymatic activity, thus influenc-
ingtheclinicaldevelopmentofthepatients(Karageorgoset
al., 2004).
Petry et al., (2005) established a correlation between
the presence of polymorphisms p.V358M and p.V376M in
MPS VI patients with a severe to intermediate phenotype.
Although their patients presented the same polymorphisms
and phenotypes, their mutations were variable. This sug-
gests that the presence of p.V358M and p.V376M is not
necessarily linked to a specific mutation, but patients with
these polymorphisms can present similar phenotypes.
Our study demonstrated that ERT was capable of sig-
nificantly reducing urinary GAG excretion in all MPS pa-
tients undergoing this treatment. Although some data
regarding the clinical evaluations were not available, this
reduction, according to the literature (Harmatz et al., 2005,
2008; Arora et al., 2007; Sifuentes et al., 2007), is strictly
related to the improvement of the patients' clinical picture.
We observed a significant reduction (p < 0.01) in uri-
nary GAG excretion in MPS I and MPS VI patients. In
MPS I, the overall reduction was of about 94% for patient
P1, and 41% for patient P2. In MPS VI patients, the overall
reduction was of about 77% for patient P7 and 73% for pa-
tient P8. Similar total reduction rates were also reported in
the literature, where reduction levels of 54% to 60% during
the initial weeks, 59% during treatment, and between 69%
and88%aftersixyearsweredescribed(Wraithetal.,2004,
2007; Sifuentes et al., 2007). Furthermore, higher enzyme
doses have been reported to be more efficient than lower
doses in achieving clinical improvements and reduction of
urinaryGAGinMPSpatientsundergoingERT(Harmatzet
al., 2005, 2008).
This is the first genetic and biochemical report on
MPS patients from northern Brazil. The mutations and
polymorphisms identified in these MPS patients were all
previously reported in Brazilian patients. Urinary GAG ex-
cretion was significantly reduced in all MPS patients
undergoing ERT, confirming the responsiveness of this
treatment. A complete molecular screening and a compre-
hensive epidemiological investigation of all patients, per-
formed at health care centers near to their birth places,
could contribute to earlier diagnosis and treatment, as well
as to a better understanding of the etiology of the disease.
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